Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). 18F-AV-1451 is a specialized radioactive PET imaging agent that is able to detect the presence of tau in the brain. In this study, the investigator will use the 18F-AV-1451 to capture images of tau in the brain. Findings from this study will likely provide insight into the mechanisms and distinctions of age-related cognitive decline and that of very early Alzheimer's disease.


Clinical Trial Description

The investigator will conduct a tau PET scan in cognitively normal older adults enrolled in the National Alzheimer's Coordinating Center (NACC) study at the University of Pennsylvania's Penn Memory Center/Alzheimer's Disease Core Center (PMC/ADC). Study Duration: Study duration will generally be a one-day study visit, but all subjects will be followed annually as part of their participation in the NACC study. Participants may be asked to obtain a longitudinal follow-up scan approximately 2-3 years after the baseline scan. Study Center(s): Penn Memory Center/Alzheimer's Disease Core Center at Perelman Center for Advanced Medicine, UPHS. Objectives: To collect Tau PET imaging in cognitively normal older adults adults and patients with Mild Cognitive Impairment (MCI), in the NACC study to determine relationship to clinical, cognitive, and other biomarker data. In particular, the investigator will examine relationship of tau PET to structural and functional measures of medial temporal lobe (MTL) subregions. Findings from this study will likely provide insight into the mechanisms and distinctions of age-related cognitive decline and that of preclinical Alzheimer's Disease. Number of Subject: 200, approximately 150 cognitively normal older adults and 50 with mild cognitive impairment. Diagnosis and Main Inclusion Criteria Eligible subjects will be NACC cohort participants who have received a consensus conference designation of "Cognitively Normal and patients with Mild Cognitive Impairment (MCI)". All participants must have had their annual NACC clinical and cognitive examination within 6 months of the tau PET imaging and an MRI scan (including high resolution imaging of medial temporal lobe regions) and amyloid PET within 12 months. Study Design: This is a cross-sectional study using the radiotracer 18F-AV-1451 to determine the relationship of tau pathology to both cross-sectional and longitudinal clinical and biomarker data of NACC cohort participants who are Cognitively Normal and patient with mild cognitive impairment . All subjects will already be part of the longitudinal cohort study, known as the "NACC" cohort, of the PMC/ADC. For the current protocol, participants will provide informed consent before beginning any study procedures. After screening assessments, participants will undergo PET scan imaging with 18F-AV-1451 and again 2 to 3 years after the baseline scan. Study Drug Administration: Subjects will receive a single IV bolus injection target dose of approximately 370 MBq (10 mCi ± 20%) of 18F-AV-1451 At approximately 75 minutes post dose, scanning will begin. An approximately 30-minute acquisition (six 5 minute intervals) will be performed. Adverse events will be monitored continuously during the imaging session. Subjects who experience any adverse event during an imaging session will not be discharged until the event has resolved or stabilized. Statistical Methodology This is a data gathering protocol to obtain molecular imaging data in a cohort of older adults without cognitive symptoms. However, specific analyses will include quantitative measures of 18F-AV-1451 within the medial temporal lobe (MTL) and its relationship to volume and thickness of MTL subregions measured with high-resolution MRI. Additional correlation and regression analyses will be performed to determine relationships between 18F-AV-1451 and cross-sectional and longitudinal measures acquired as part of each individuals participation in the NACC longitudinal cohort study, including, but not limited to, MRI imaging, neurocognitive testing, demographic information, genetic data, and clinical outcomes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03189485
Study type Observational
Source University of Pennsylvania
Contact Jackie Lane, MPH
Phone 215-662-7057
Email jacqueline.lane@pennmedicine.upenn.edu
Status Recruiting
Phase
Start date November 22, 2017
Completion date May 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04779671 - Effects of the Fully Immersive VR Cognitive Training Based on Leisure Activities for the Elderly With MCI and SCD. N/A
Recruiting NCT04466735 - BRain Energy Activation With Ketones to Prevent Alzheimer's Disease Phase 2
Enrolling by invitation NCT06135740 - Impact of Nutrition, Sleep, and Physical Activity on Intellectual Function and Muscle Mass in Older Adults N/A
Recruiting NCT06402370 - Amyloid PET in Patients With Mild Cognitive Impairment and Early Dementia
Active, not recruiting NCT03069391 - The Interactive Physical and Cognitive Exercise System N/A
Recruiting NCT05460468 - Neuromodulation of Memory in Aging N/A
Recruiting NCT05563298 - Neuro RX Gamma for Amnestic Mild Cognitive Impairment (aMCI) N/A
Completed NCT04095377 - Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.
Recruiting NCT05771064 - Promoting In-Home Activities at a Memory & Aging Clinic Phase 1
Completed NCT03224988 - Bilateral Brain Dynamics in Cognition and Aging
Recruiting NCT06335836 - The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
Completed NCT05380284 - Senior Driving Simulation Training for Subjective Cognitive Decline and Mild Cognitive Impairment N/A
Recruiting NCT04897464 - Validation Study of a New Digital Treatment Test N/A
Active, not recruiting NCT02380573 - Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease Phase 2
Completed NCT04243642 - PJ-011726 IntelliSpace Cognition MCI Study
Recruiting NCT01830998 - Early Detection of Cognitive Dysfunction in Diabetes N/A
Recruiting NCT03900936 - Detecting Dementia Earlier
Recruiting NCT06264557 - Cognitive Therapy Software for Improving Cognitive Function for Patients With Mild Cognitive Impairment N/A
Not yet recruiting NCT06223438 - Detecting an MCI and Amyloid Digital Neuro Signature(DNS) Using Altoida's Multimodal Digital Biomarkers.
Not yet recruiting NCT05682469 - Effects and Mechanism of the Fully Immersive Virtual Reality Cognitive Training Based on Leisure Activities N/A